(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -14.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.39%.
Spero Therapeutics's revenue in 2026 is $46,997,000.On average, 3 Wall Street analysts forecast SPRO's revenue for 2026 to be $47,519,619, with the lowest SPRO revenue forecast at $45,656,104, and the highest SPRO revenue forecast at $48,917,255. On average, 3 Wall Street analysts forecast SPRO's revenue for 2027 to be $190,078,475, with the lowest SPRO revenue forecast at $182,624,417, and the highest SPRO revenue forecast at $195,669,019.
In 2028, SPRO is forecast to generate $1,966,124,229 in revenue, with the lowest revenue forecast at $1,889,021,318 and the highest revenue forecast at $2,023,951,412.